Article Text

Download PDFPDF
Randomised controlled trial
Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings
  1. Angela Robertson Bazzi
  1. Boston University School of Public Health, Boston, Massachusetts, USA
  1. Correspondence to : Professor Angela Robertson Bazzi, Boston University School of Public Health, 801 Massachusetts Ave, 442E, Boston, MA 02118, USA; abazzi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Randomised placebo-controlled trials have demonstrated the efficacy of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV-1 acquisition in diverse international populations including men who have sex with men (MSM).1–3 However, concerns regarding adherence to daily regimens and potential risk compensation (eg, increased engagement in condomless sex) in real-world settings have contributed to skepticism and delayed implementation of PrEP. The PROUD open-label randomised pilot trial tested the effectiveness of daily oral PrEP delivered to high-risk MSM through 13 sexual health …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.